


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:35Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405030" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405030</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Urol</journal-id><journal-id journal-id-type="iso-abbrev">World J Urol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>World Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">0724-4983</issn><issn pub-type="epub">1433-8726</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405030</article-id><article-id pub-id-type="pmcid-ver">PMC12405030.1</article-id><article-id pub-id-type="pmcaid">12405030</article-id><article-id pub-id-type="pmcaiid">12405030</article-id><article-id pub-id-type="pmid">40897946</article-id><article-id pub-id-type="doi">10.1007/s00345-025-05895-9</article-id><article-id pub-id-type="publisher-id">5895</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Comparing the clinical outcomes and learning curves of prostatic urethral lift performed by experienced versus na&#239;ve urologists</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hsieh</surname><given-names initials="TY">Tsung-Yi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6054-0728</contrib-id><name name-style="western"><surname>Hong</surname><given-names initials="JH">Jian-Hua</given-names></name><address><email>d07528012@ntu.edu.tw</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chueh</surname><given-names initials="JSC">Jeff Shih-Chieh</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03nteze27</institution-id><institution-id institution-id-type="GRID">grid.412094.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 7815</institution-id><institution>Department of Urology, </institution><institution>National Taiwan University Hospital, </institution></institution-wrap>7 Chung Shan South Road, Taipei, 10002 Taiwan (R.O.C.) </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>43</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><elocation-id>532</elocation-id><history><date date-type="received"><day>3</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="345_2025_Article_5895.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To characterize the learning process by comparing the clinical outcomes and learning curves of prostatic urethral lift (PUL) performed by experienced versus na&#239;ve urologists.</p></sec><sec><title>Methods</title><p id="Par2">Consecutive patients treated with PUL at a tertiary center by an experienced urologist with &gt;&#8201;100 PUL cases or by na&#239;ve urologists with no prior PUL experience were included in this study. Perioperative parameters, functional outcomes, complications, and retreatment rates were compared. Learning curves were assessed using the cumulative sum (CUSUM) methodology. Multivariate regression identified predictors of operative time.</p></sec><sec><title>Results</title><p id="Par3">The median operative time was 20.0&#160;min in both groups. Overall, the International Prostate Symptoms Score total decreased by a median of 9.0 points, quality of life score decreased by a median of 2.0 points, peak urinary flow rate increased by a median of 4.3&#160;ml/sec, and post-void residual volume decreased by a median of 19.8&#160;ml. There were no significant differences between the two groups in functional outcomes, complication rate, or operative time. CUSUM analysis revealed a three-phase learning curve, with proficiency achieved after 5 to 8 cases. Operative time was independently associated with obstructive median lobe (<italic toggle="yes">P</italic>&#8201;=&#8201;0.003), number of implants (<italic toggle="yes">P</italic>&#8201;=&#8201;0.005), implant deployment failure (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and experience (<italic toggle="yes">P</italic>&#8201;=&#8201;0.024).</p></sec><sec><title>Conclusion</title><p id="Par4">PUL can be safely and effectively performed by both experienced and na&#239;ve urologists with comparable outcomes. The learning curve is short but defined with proficiency achieved after 5 to 8 cases.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prostatic urethral lift</kwd><kwd>Lower urinary tract symptoms</kwd><kwd>Prostate enlargement</kwd><kwd>Bladder outlet obstruction</kwd><kwd>Minimally invasive surgical therapies</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Lower urinary tract symptoms (LUTS) affect up to 90% of men aged 45 to 80, and are commonly attributed to bladder outlet obstruction (BOO) secondary to benign prostatic enlargement [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. These symptoms can significantly impair quality of life (QOL), particularly in older men, who have an increased incidence of moderate-to-severe LUTS and acute urinary retention (AUR) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Surgical management for bothersome prostatic BOO is indicated when conservative management or medical therapy is inadequate, intolerable, or undesired [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The past decade has seen a large expansion of innovative surgical options, including minimally invasive surgical therapies (MISTs) that aim to reduce adverse events, such as bleeding or secondary sexual dysfunction [<xref ref-type="bibr" rid="CR7">7</xref>]. The prostatic urethral lift (PUL) has emerged as a non-ablative surgical option that can rapidly improve symptoms while minimizing perioperative morbidity, postoperative urinary catheter use, and erectile and ejaculatory dysfunction [<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, recent studies have demonstrated the efficacy of PUL in patients with obstructive median lobes, suggesting its expanding role in anatomically complex cases [<xref ref-type="bibr" rid="CR9">9</xref>]. These advantages have led PUL to be increasingly preferred by urologists and patients seeking less invasive managements [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par6">As the indications for PUL broaden to potentially require more advanced technical skills, ensuring safe and effective outcomes by urologists of varying experience levels has become a priority. The current training model for PUL includes online courses, simulation and proctored procedures. However, clear benchmarks for when a na&#239;ve urologist achieves procedural proficiency in live cases are lacking, and the learning curve for PUL remains poorly characterized [<xref ref-type="bibr" rid="CR11">11</xref>]. Defining the PUL learning curve is essential for optimizing training and maintaining consistent outcomes, particularly during the early adoption phase. Although PUL is often described as having a short learning curve, this assumption has not been formally studied and does not account for more complex cases [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. This study aims to address this gap in literature by comparing the clinical outcomes and learning curves of PUL performed by experienced and na&#239;ve urologists.</p></sec><sec id="Sec2"><title>Patients and methods</title><sec id="Sec3"><title>Study population and endpoints</title><p id="Par7">This study was approved by the Research Ethics Committee of the National Taiwan University Hospital (202504082RIND). All consecutive patients undergoing PUL from November 2022 to April 2025 at a single tertiary referral center were included in this retrospective study. Patients without a postoperative follow-up visit were excluded. PUL procedures were performed by either an experienced urologist with over 100 cases of PUL or by na&#239;ve urologists with no PUL experience prior to enrollment. All PUL-na&#239;ve urologists were otherwise experienced in endourologic procedures, completed a PUL simulation training program, and were supervised by a PUL-experienced urologist during their initial PUL cases.</p><p id="Par8">Patient characteristics and clinical parameters&#8212;including age, body mass index, American Society of Anesthesiologists (ASA) score, prostate volume, prostate-specific antigen (PSA) level, preoperative catheter dependence, and preoperative and postoperative International Prostate Symptom Scores (IPSS), peak urinary flow rates (Qmax), and post-void residual volumes (PVR)&#8212;were collected. Perioperative and functional outcomes&#8212;such as operative time, intraoperative implant failure rates, changes in IPSS total, IPSS quality of life (QOL), Qmax, and PVR, complication rates, and retreatment rates&#8212;were compared between the experienced and na&#239;ve urologists.</p></sec><sec id="Sec4"><title>Procedure</title><p id="Par9">PUL is performed via delivering small permanent implants transurethrally under endoscopic guidance to pull apart the obstructing lobes and create an open anterior channel through the prostatic fossa. Prior to deployment, rigid cystoscopy is performed to plan the target implant locations. The implant delivery device (UroLift System, NeoTract-Teleflex, Pleasanton, CA, USA), which houses a 2.9&#160;mm telescope, is then inserted transurethrally in a 20 Fr. sheath and angled laterally, usually at the 10 and 2 o&#8217;clock position to compress the obstructive lobe. The implant, composed of a monofilament suture with a nitinol capsular tab on one end and a stainless steel urethral end-piece on the other, is deployed by a 19 gauge needle through the lobe. As the needle is withdrawn, the capsular tab anchors into the prostatic capsule. The suture is then tensioned and cut to the width of the compressed lobe, and the urethral end-piece secures the implant in place. The deployed implants are therefore customized to the prostate anatomy. After the implants are delivered, a urethral catheter is inserted.</p></sec><sec id="Sec5"><title>Learning curve analysis</title><p id="Par10">Operative time was used for learning curve analysis. The cumulative sum (CUSUM) method was used to construct the learning curves for the operative time of the experienced urologist and the na&#239;ve urologist with the most cases during this study period. For each CUSUM curve, we define a turning point as the point when operative times begin to decrease and a plateau as the period during which operative time stabilizes.</p></sec><sec id="Sec30"><title>Statistical analysis</title><p id="Par11">The distributions of demographic and clinical characteristics of the patients were described as median with interquartile range (IQR) for continuous variables and as frequency with percentages (%) for categorical variables. Chi-squared test was used to compare categorical variables and Kruskal-Wallis test was used to compare continuous variables. Wilcoxon signed-rank test was used to compare the preoperative and postoperative IPSS total, QOL, Qmax, and PVR. Missing data were assumed to be missing at random and were handled with pairwise deletion. A P-value of &lt;&#8201;0.05 was considered statistically significant. Linear regression model was used for the univariate analysis. Variables with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.10 were then included in the multivariate analysis. A stepwise multiple regression model with variable inclusion if <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.1 and exclusion if <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.15 was used to evaluate the association between operative time and predictive factors. The P values&#8201;&#8804;&#8201;0.025 were considered statistically significant after a Holm-Bonferroni stepdown adjustment for multiple testing using an &#945;&#8201;&#8804;&#8201;0.05. All data were analyzed using R software, version 4.5.0 (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link>).</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par12">A total of 67 consecutive patients who received PUL due to prostatic BOO between November 2022 and April 2025 were included in the study. Among them, 40 (59.7%) patients were treated by a PUL-experienced urologist and 27 (40.3%) patients were treated by na&#239;ve urologists with no PUL experience prior to the study. Overall, the median age of the patients was 69.2 (IQR 63.9&#8211;74.9) years. The median ASA score was 2 (IQR 2&#8211;3). The median PSA was 1.8 (IQR 0.9&#8211;3.4) ml. The median prostate volume was 46.8 (IQR 37.1&#8211;59.7) ml. An obstructive median lobe was found in 9 (13.4%) patients. Baseline median IPSS total was 20.0 (IQR 16.0&#8211;25.5) and median IPSS QOL was 4.0 (IQR 3.0&#8211;5.0). The median Qmax was 10.0 (IQR 7.3&#8211;13.0) ml/sec. The median PVR was 52.0 (IQR 19.0&#8211;109.3) ml. Preoperative catheter dependence was observed in 9.0% of the patients. There were no statistically significant differences in the baseline demographics and characteristics between the experienced urologist group and the na&#239;ve urologist group (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par13">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of patients receiving prostatic urethral lift according to prior experience</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Overall</th><th align="left" colspan="2" rowspan="1">Experienced urologist</th><th align="left" colspan="2" rowspan="1">Na&#239;ve urologist</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Patients, n (%)</td><td align="left" colspan="1" rowspan="1">67</td><td align="left" colspan="1" rowspan="1">(100.0)</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">(59.7)</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">(40.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age, year, median (IQR)</td><td align="left" colspan="1" rowspan="1">69.2</td><td align="left" colspan="1" rowspan="1">(63.9&#8211;74.9)</td><td align="left" colspan="1" rowspan="1">68.7</td><td align="left" colspan="1" rowspan="1">(63.8&#8211;73.3)</td><td align="left" colspan="1" rowspan="1">70.5</td><td align="left" colspan="1" rowspan="1">(64.2&#8211;76.2)</td><td char="." align="char" colspan="1" rowspan="1">0.413</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI, kg/m<sup>2</sup>, median (IQR)</td><td align="left" colspan="1" rowspan="1">24.8</td><td align="left" colspan="1" rowspan="1">(23.6&#8211;27.4)</td><td align="left" colspan="1" rowspan="1">24.7</td><td align="left" colspan="1" rowspan="1">(23.6&#8211;27.9)</td><td align="left" colspan="1" rowspan="1">25.1</td><td align="left" colspan="1" rowspan="1">(23.2&#8211;26.6)</td><td char="." align="char" colspan="1" rowspan="1">0.888</td></tr><tr><td align="left" colspan="1" rowspan="1">ASA score, median (IQR)</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">(2&#8211;3)</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(2&#8211;3)</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">(2&#8211;3)</td><td char="." align="char" colspan="1" rowspan="1">0.227</td></tr><tr><td align="left" colspan="1" rowspan="1">Prostate specific antigen, ng/ml, median (IQR)</td><td align="left" colspan="1" rowspan="1">1.8</td><td align="left" colspan="1" rowspan="1">(0.9&#8211;3.4)</td><td align="left" colspan="1" rowspan="1">1.8</td><td align="left" colspan="1" rowspan="1">(0.7&#8211;3.1)</td><td align="left" colspan="1" rowspan="1">1.9</td><td align="left" colspan="1" rowspan="1">(0.9&#8211;4.0)</td><td char="." align="char" colspan="1" rowspan="1">0.604</td></tr><tr><td align="left" colspan="1" rowspan="1">Prostate volume, ml, median (IQR)</td><td align="left" colspan="1" rowspan="1">46.8</td><td align="left" colspan="1" rowspan="1">(37.1&#8211;59.7)</td><td align="left" colspan="1" rowspan="1">46.5</td><td align="left" colspan="1" rowspan="1">(32.7&#8211;57.8)</td><td align="left" colspan="1" rowspan="1">51.6</td><td align="left" colspan="1" rowspan="1">(38.6&#8211;61.0)</td><td char="." align="char" colspan="1" rowspan="1">0.436</td></tr><tr><td align="left" colspan="1" rowspan="1">Presence of obstructive median lobe, n (%)</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">(13.4)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">(12.5)</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">(14.8)</td><td char="." align="char" colspan="1" rowspan="1">0.787</td></tr><tr><td align="left" colspan="1" rowspan="1">IPSS total, median (IQR)</td><td align="left" colspan="1" rowspan="1">20.0</td><td align="left" colspan="1" rowspan="1">(16.0&#8211;25.5)</td><td align="left" colspan="1" rowspan="1">20.0</td><td align="left" colspan="1" rowspan="1">(14.5&#8211;25.0)</td><td align="left" colspan="1" rowspan="1">19.0</td><td align="left" colspan="1" rowspan="1">(16.8&#8211;26.3)</td><td char="." align="char" colspan="1" rowspan="1">0.844</td></tr><tr><td align="left" colspan="1" rowspan="1">IPSS QOL, median (IQR)</td><td align="left" colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">(3.0&#8211;5.0)</td><td align="left" colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">(3.0&#8211;4.5)</td><td align="left" colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">(3.8&#8211;5.0)</td><td char="." align="char" colspan="1" rowspan="1">0.352</td></tr><tr><td align="left" colspan="1" rowspan="1">Qmax, ml/sec, median (IQR)</td><td align="left" colspan="1" rowspan="1">10.0</td><td align="left" colspan="1" rowspan="1">(7.3&#8211;13.0)</td><td align="left" colspan="1" rowspan="1">10.5</td><td align="left" colspan="1" rowspan="1">(8.0&#8211;13.1)</td><td align="left" colspan="1" rowspan="1">9.1</td><td align="left" colspan="1" rowspan="1">(5.0&#8211;12.0)</td><td char="." align="char" colspan="1" rowspan="1">0.103</td></tr><tr><td align="left" colspan="1" rowspan="1">PVR, ml, median (IQR)</td><td align="left" colspan="1" rowspan="1">52.0</td><td align="left" colspan="1" rowspan="1">(19.0&#8211;109.3)</td><td align="left" colspan="1" rowspan="1">54.0</td><td align="left" colspan="1" rowspan="1">(20.2&#8211;109.5)</td><td align="left" colspan="1" rowspan="1">32.0</td><td align="left" colspan="1" rowspan="1">(15.8&#8211;128.5)</td><td char="." align="char" colspan="1" rowspan="1">0.694</td></tr><tr><td align="left" colspan="1" rowspan="1">Preoperative catheter dependence, n (%)</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">(9.0)</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">(5.0)</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">(14.8)</td><td char="." align="char" colspan="1" rowspan="1">0.171</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ASA</italic> American Society of Anesthesiologists, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">IPSS</italic> International Prostate Symptom Score, <italic toggle="yes">IQR</italic> interquartile range, <italic toggle="yes">PVR</italic> post-void residual volume, <italic toggle="yes">Qmax</italic>, peak urinary flow rate, <italic toggle="yes">QOL</italic> Quality of life</p></table-wrap-foot></table-wrap>
</p><sec id="Sec8"><title>Intraoperative and postoperative outcomes</title><p id="Par14">The median operative time was 20.0 (IQR 15.0&#8211;25.0) minutes and was comparable between the experienced urologist and na&#239;ve urologist cohorts (20.0&#160;min vs. 20.0&#160;min, <italic toggle="yes">P</italic>&#8201;=&#8201;0.511). The median number of implants implanted was 5 (IQR 4&#8211;6). Intraoperative deployment failure occurred in 16.4% of the procedures, comprising 7 cases of bone strike, 3 cases of implant dislodgement, and 1 case of incomplete suture cutting. The number of implants deployed and intraoperative deployment failure rates were also similar between the two groups (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par15">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Intraoperative and postoperative outcomes according to prior experience</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Overall</th><th align="left" colspan="2" rowspan="1">Experienced urologist</th><th align="left" colspan="2" rowspan="1">Na&#239;ve urologist</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Operative time, min, median (IQR)</td><td align="left" colspan="1" rowspan="1">20.0</td><td align="left" colspan="1" rowspan="1">(15.0&#8211;25.0)</td><td align="left" colspan="1" rowspan="1">20.0</td><td align="left" colspan="1" rowspan="1">(15.0&#8211;25.0)</td><td align="left" colspan="1" rowspan="1">20.0</td><td align="left" colspan="1" rowspan="1">(15.0&#8211;28.8)</td><td char="." align="char" colspan="1" rowspan="1">0.511</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of implants, median (IQR)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">(4&#8211;6)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">(4&#8211;6)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">(4&#8211;6)</td><td char="." align="char" colspan="1" rowspan="1">0.926</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative deployment failure, n (%)</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">(16.4)</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">(15.0)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">(18.5)</td><td char="." align="char" colspan="1" rowspan="1">0.705</td></tr><tr><td align="left" colspan="1" rowspan="1">Change in IPSS total, median (IQR)</td><td align="left" colspan="1" rowspan="1">-9.0</td><td align="left" colspan="1" rowspan="1">(-14.0 &#8211; -5.0)</td><td align="left" colspan="1" rowspan="1">-9.5</td><td align="left" colspan="1" rowspan="1">(-17.0 &#8211; -5.5)</td><td align="left" colspan="1" rowspan="1">-9.0</td><td align="left" colspan="1" rowspan="1">(-13.8 &#8211; -3.5)</td><td char="." align="char" colspan="1" rowspan="1">0.558</td></tr><tr><td align="left" colspan="1" rowspan="1">% Change in IPSS total, median (IQR)</td><td align="left" colspan="1" rowspan="1">-50.0</td><td align="left" colspan="1" rowspan="1">(-66.7 &#8211; -35.0)</td><td align="left" colspan="1" rowspan="1">-57.9</td><td align="left" colspan="1" rowspan="1">(-66.7 &#8211; -40.8)</td><td align="left" colspan="1" rowspan="1">-44.4</td><td align="left" colspan="1" rowspan="1">(-63.2 &#8211; -27.1)</td><td char="." align="char" colspan="1" rowspan="1">0.324</td></tr><tr><td align="left" colspan="1" rowspan="1">Change in IPSS QOL, median (IQR)</td><td align="left" colspan="1" rowspan="1">-2.0</td><td align="left" colspan="1" rowspan="1">(-2.5 &#8211; -1.0)</td><td align="left" colspan="1" rowspan="1">-2.0</td><td align="left" colspan="1" rowspan="1">(-2.0 &#8211; -1.0)</td><td align="left" colspan="1" rowspan="1">-2.0</td><td align="left" colspan="1" rowspan="1">(-3.0 &#8211; -1.0)</td><td char="." align="char" colspan="1" rowspan="1">0.664</td></tr><tr><td align="left" colspan="1" rowspan="1">% Change in IPSS QOL, median (IQR)</td><td align="left" colspan="1" rowspan="1">-40.0</td><td align="left" colspan="1" rowspan="1">(-60.0 &#8211; -29.2)</td><td align="left" colspan="1" rowspan="1">-40.0</td><td align="left" colspan="1" rowspan="1">(-83.3 &#8211; -25.0)</td><td align="left" colspan="1" rowspan="1">-45.0</td><td align="left" colspan="1" rowspan="1">(-60.0 &#8211; -33.3)</td><td char="." align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" colspan="1" rowspan="1">Change in Qmax, ml/sec, median (IQR)</td><td align="left" colspan="1" rowspan="1">4.3</td><td align="left" colspan="1" rowspan="1">(1.2&#8211;7.9)</td><td align="left" colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">(1.7&#8211;7.8)</td><td align="left" colspan="1" rowspan="1">5.7</td><td align="left" colspan="1" rowspan="1">(1.0&#8211;10.3)</td><td char="." align="char" colspan="1" rowspan="1">0.439</td></tr><tr><td align="left" colspan="1" rowspan="1">% Change in Qmax, median (IQR)</td><td align="left" colspan="1" rowspan="1">41.7</td><td align="left" colspan="1" rowspan="1">(19.5&#8211;101.9)</td><td align="left" colspan="1" rowspan="1">39.2</td><td align="left" colspan="1" rowspan="1">(20.5&#8211;60.0)</td><td align="left" colspan="1" rowspan="1">76.0</td><td align="left" colspan="1" rowspan="1">(10.6&#8211;137.5)</td><td char="." align="char" colspan="1" rowspan="1">0.290</td></tr><tr><td align="left" colspan="1" rowspan="1">Change in PVR, ml, median (IQR)</td><td align="left" colspan="1" rowspan="1">-19.8</td><td align="left" colspan="1" rowspan="1">(-69.7&#8211;3.8)</td><td align="left" colspan="1" rowspan="1">-22.5</td><td align="left" colspan="1" rowspan="1">(-68.6&#8211;7.7)</td><td align="left" colspan="1" rowspan="1">-17.0</td><td align="left" colspan="1" rowspan="1">(-295.3 &#8211; -3.3)</td><td char="." align="char" colspan="1" rowspan="1">0.367</td></tr><tr><td align="left" colspan="1" rowspan="1">% Change in PVR, median (IQR)</td><td align="left" colspan="1" rowspan="1">-59.3</td><td align="left" colspan="1" rowspan="1">(-81.0&#8211;27.3)</td><td align="left" colspan="1" rowspan="1">-60.0</td><td align="left" colspan="1" rowspan="1">(-76.6&#8211;56.1)</td><td align="left" colspan="1" rowspan="1">-58.5</td><td align="left" colspan="1" rowspan="1">(-94.0 &#8211; -11.3)</td><td char="." align="char" colspan="1" rowspan="1">0.399</td></tr><tr><td align="left" colspan="1" rowspan="1">Clavien-Dindo Classification grade&#8201;&#8805;&#8201;3 complication, n (%)</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">(3.0)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">(0)</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">(7.4)</td><td char="." align="char" colspan="1" rowspan="1">0.083</td></tr><tr><td align="left" colspan="1" rowspan="1">Retreatment, n (%)</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">(1.5)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">(0)</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">(3.7)</td><td char="." align="char" colspan="1" rowspan="1">0.224</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IPSS</italic> International Prostate Symptom Score, <italic toggle="yes">IQR</italic> interquartile range, <italic toggle="yes">PVR</italic> post-void residual volume, <italic toggle="yes">Qmax</italic> peak urinary flow rate, <italic toggle="yes">QOL</italic> Quality of life</p></table-wrap-foot></table-wrap>
</p><p id="Par16">After a median follow-up of 6 months, patients demonstrated significant improvements in postoperative functional outcomes. IPSS total decreased by a median of 9.0 (IQR 5.0&#8211;14.0), which was a 50.0% reduction. IPSS QOL decreased by a median of 2.0 (IQR 1.0&#8211;2.5), which was a 40.0% reduction. Qmax increased by a median of 4.3 (IQR 1.2&#8211;7.9) ml/sec, which was a 41.7% increase. PVR decreased by a median of 19.8 (IQR 3.8&#8211;69.7) ml, which was a 59.3% decrease. These improvements were observed significantly in both the experienced and na&#239;ve urologist groups. However, no significant differences were found between the two groups in the magnitude of change in IPSS total, QOL, Qmax, or PVR (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par17">Overall, 16.4% of patients suffered from complications, the majority of which were postoperative hematuria (9.0%) and urinary retention (7.5%). These complications were mostly transient and managed with short-term bladder irrigation or urinary catheters. However, Clavien-Dindo grade&#8201;&#8805;&#8201;3 complications occurred in 2 (3.0%) patients, who both had hematuria that needed endoscopic blood clot evacuation. One patient in the na&#239;ve urologist group received bipolar transurethral resection of the prostate 6 months after the PUL procedure due to persistent BOO. The resection was confined to the median lobe, with the PUL implants in the lateral lobes preserved. There were no differences between the experienced and na&#239;ve urologist groups in the complication and retreatment rates (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec9"><title>Learning curve</title><p id="Par18">Figure <xref rid="Fig1" ref-type="fig">1</xref> shows CUSUM charts with learning curves for operative time of the experienced urologist (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a) and the na&#239;ve urologist (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b). For the experienced urologist, there was a gradual upward trend with fluctuations initially, followed by a gradual downward trend after 26 cases (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a). For the na&#239;ve urologist, a three-phase learning curve may be identified from the CUSUM chart: an initial upward trend reaching the turning point at case 5 (learning phase), followed by stabilizing performance (proficiency phase), followed by a strong downward trend after case 8 (competency phase) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b). Multivariable regression analysis showed that independent predictors of operative time included the presence of obstructive median lobe (<italic toggle="yes">P</italic>&#8201;=&#8201;0.003), number of implants (<italic toggle="yes">P</italic>&#8201;=&#8201;0.005), intraoperative implant deployment failure (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and the number of cases (&#8804;&#8201;5) the urologist has performed (<italic toggle="yes">p</italic>&#8201;=&#8201;0.024) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par19">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>CUSUM charts of operative times for the experienced urologist (<bold>a</bold>) and the na&#239;ve urologist (<bold>b</bold>). Cumulative deviation from the mean operative time is plotted against consecutive case number. Vertical dotted lines indicate the turning points for different phases</p></caption><graphic id="d33e858" position="float" orientation="portrait" xlink:href="345_2025_5895_Fig1_HTML.jpg"/></fig>
</p><p id="Par20">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Factors associated with operative time</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Univariate</th><th align="left" colspan="2" rowspan="1">Multivariate</th></tr><tr><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1">P-value</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">[-0.16, 0.42]</td><td align="left" colspan="1" rowspan="1">0.387</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BMI</td><td align="left" colspan="1" rowspan="1">[-1.01, 0.51]</td><td align="left" colspan="1" rowspan="1">0.514</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ASA score</td><td align="left" colspan="1" rowspan="1">[-6.39, 2.42]</td><td align="left" colspan="1" rowspan="1">0.372</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Prostate specific antigen</td><td align="left" colspan="1" rowspan="1">[-0.46, 2.26]</td><td align="left" colspan="1" rowspan="1">0.190</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Prostate volume</td><td align="left" colspan="1" rowspan="1">[0.02, 0.27]</td><td align="left" colspan="1" rowspan="1">0.029</td><td align="left" colspan="1" rowspan="1">[-0.29, 0.02]</td><td align="left" colspan="1" rowspan="1">0.065</td></tr><tr><td align="left" colspan="1" rowspan="1">Presence of obstructive median lobe</td><td align="left" colspan="1" rowspan="1">[4.81, 18.11]</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">[3.20, 16.54]</td><td align="left" colspan="1" rowspan="1">0.003*</td></tr><tr><td align="left" colspan="1" rowspan="1">Preoperative catheter dependence</td><td align="left" colspan="1" rowspan="1">[-6.14, 11.09]</td><td align="left" colspan="1" rowspan="1">0.568</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Number of implants</td><td align="left" colspan="1" rowspan="1">[1.50, 5.32]</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">[1.01, 5.88]</td><td align="left" colspan="1" rowspan="1">0.005*</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative deployment failure</td><td align="left" colspan="1" rowspan="1">[3.56, 15.97]</td><td align="left" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1">[5.49, 16.39]</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001*</td></tr><tr><td align="left" colspan="1" rowspan="1">Case number&#8201;&#8804;&#8201;5</td><td align="left" colspan="1" rowspan="1">[0.04, 11.4]</td><td align="left" colspan="1" rowspan="1">0.048</td><td align="left" colspan="1" rowspan="1">[0.63, 9.73]</td><td align="left" colspan="1" rowspan="1">0.024*</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ASA</italic> American Society of Anesthesiologists, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">CI</italic> confidence interval</p><p>* Statistically significant</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par21">In recent years, MISTs have seen increasing preference in the treatment of benign prostate enlargement due to its minimally invasive nature, effectiveness, and safety. As a non-ablative technique, PUL is often favored due to its rapid effect and preservation of sexual and ejaculatory function [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The efficacy, durability, and safety of PUL have been demonstrated in previous studies. For example, the L.I.F.T. study reported a decrease in IPSS total by 7.85 and an increase in Qmax by 3.21&#160;ml/sec at 60-months follow-up [<xref ref-type="bibr" rid="CR8">8</xref>]. The results of the L.I.F.T. study have been corroborated by several other studies [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>]. Our results also show similar rates of improvement with a 9.0 reduction in IPSS total and a 4.3&#160;ml/sec increase in Qmax.</p><p id="Par22">The most common complications observed in our study were hematuria and urinary retention, both of which were generally mild and managed conservatively with short-term catheterization. However, two patients (3.0%) experienced hematuria severe enough to require endoscopic clot evacuation. These findings are consistent with prior studies. For example, S&#248;nksen et al. reported Clavien-Dindo grade 1 bleeding in 39% of patients and grade 3b bleeding requiring intervention in 2% of cases [<xref ref-type="bibr" rid="CR18">18</xref>]. Retreatment was required in only one patient (1.5%) in our cohort, which aligns with previously reported 1-year retreatment rates ranging from 2 to 5.9% [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Taken together, the safety and efficacy outcomes observed in our cohort were comparable to those reported in the literature.</p><p id="Par23">This study provides the first study that defines the learning curve associated with PUL. The CUSUM chart for the na&#239;ve urologist revealed three discernible phases, with turning points at case 5 and case 8. The first five cases represented the initial learning period, during which operative times were consistently above the mean. The next several cases marked the development of proficiency, as operative times stabilize and approach the mean. After eight cases, there is a consistent downward trend in operative time, indicating that the urologist had reached stable competency. In contrast, the CUSUM chart for the experienced surgeon showed only a gradual downward trajectory in operative time after approximately 26 cases. This is reflective of the diminishing marginal benefit of additional experience if a certain level of competency has already been reached, especially in a procedure with a short learning curve.</p><p id="Par24">Similar to PUL, Rez&#363;m water vapor thermal therapy is generally considered to have a rapid learning curve [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In contrast, holmium laser enucleation of the prostate (HoLEP), bipolar enucleation, and Aquablation require precise identification of the enucleation plane or the resection contour and efficient hemostasis, contributing to a steeper learning curve. HoLEP and bipolar enucleation typically require 20&#8211;50 cases to reach proficiency [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>]. Aquablation may require 38 cases to achieve an acceptable success rate [<xref ref-type="bibr" rid="CR25">25</xref>]. Although these modalities are all effective treatment options for BOO, PUL offers a more accessible learning curve.</p><p id="Par25">Despite its relatively short learning curve, PUL is not devoid of technical challenges. Intraoperative implant deployment failures occurred in the experienced urologist and na&#239;ve urologist groups with similar rates (15.0% vs. 18.5%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.926). Most of the deployment failure was attributed to bone strike&#8212;contact of the needle with the pelvic bone. None of the deployment failure cases led to further complications. Although literature on the rate of implant mis-deployment is very limited, several reports have addressed the issues of bone strike, device failure, and implant dislodgement [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. There have also been case reports of bone strikes during PUL that developed into pelvic hematomas [<xref ref-type="bibr" rid="CR27">27</xref>]. The array of difficulties reported indicates that the technical skills required of PUL should not be underestimated. Understandably, intraoperative implant deployment failure was highly predictive of operative time (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) in our multivariate analysis.</p><p id="Par26">Although current EAU and AUA guidelines recommend PUL for patients without obstructive median lobes, evidence suggests that with proper technique, PUL may still have a role in these cases [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Ruktalis et al. showed in the MedLift Study that the obstructive median lobe can be effectively treated by pulling the intravesical tissue into the prostatic fossa and affixing with implants to either side of the urethra [<xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, while prostate volumes&#8201;&gt;&#8201;80&#160;ml have traditionally been managed by other modalities, such as HoLEP or simple prostatectomy [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], studies have also demonstrated that PUL can produce fair clinical outcomes in these larger prostates [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Patients with smaller prostates, shorter prostate urethral lengths, or sharper urethral angles, and patients with AUR can also pose unique challenges to procedural success due to altered anatomy and bladder urodynamics [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. These scenarios require more nuanced techniques and judgment.</p><p id="Par27">Our study included patients with obstructive median lobes as well as larger and smaller prostates, thereby reflecting a real-world clinical setting and supporting the broad applicability of our findings. The multivariate analysis showed that the presence of obstructive median lobe was associated with increased operative time (<italic toggle="yes">P</italic>&#8201;=&#8201;0.003). These factors may explain the occasional variability in operative time even after the proficiency plateau has been reached.</p><p id="Par28">The multivariate analysis showed that operative time was significantly associated with the number of cases the urologist has performed (<italic toggle="yes">P</italic>&#8201;=&#8201;0.024). Current training for PUL typically involves simulations and proctored procedures. However, no framework existed for the optimal training structure or the number of proctored cases [<xref ref-type="bibr" rid="CR11">11</xref>]. Our findings could help inform supervision and potentially credential programs for na&#239;ve urologists aiming to adopt a novel technique.</p><p id="Par29">This study has several limitations. The retrospective non-randomized design is inherently subject to selection and information biases. Supervision by the experienced urologist in the early cases was not standardized. The presence of supervision may introduce potential observer bias. The relatively small sample size from a single center limits the ability to detect rare complications or subtle intergroup differences in clinical outcomes. Operative time as a sole surrogate for defining the learning curve may not fully capture other dimensions of procedural competence, such as implant positioning accuracy, patient satisfaction, or long-term outcomes.</p><p id="Par30">PUL can be safely and effectively performed by both experienced and na&#239;ve urologists, with proficiency typically achieved after 5&#8211;8 cases. Although it has a short learning curve, anatomical variations such as median lobes may require more nuanced techniques and careful planning. Our findings support PUL as an accessible, minimally invasive treatment for BOO.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>T.H. and H.H. conceptualized and designed the study, performed data collection, analyzed data, and drafted the original manuscript. H.H. and J.C. coordinated data collection and critically reviewed the manuscript. All authors reviewed and approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funding from any agency in the public, commercial, or not-for-profit sectors was received for this study.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and analyzed in the current study are available from the corresponding author on request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par31">The authors declare no competing interests.</p></notes><notes id="FPar3"><title>Ethical approval</title><p id="Par32">This study was reviewed and approved by the Research Ethics Committee of the National Taiwan University Hospital (202504082RIND). The study is retrospective in nature and does not involve ongoing human subject studies. Formal consent is not required for this retrospective review.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><collab>McVary KT</collab></person-group><article-title>BPH: epidemiology and comorbidities</article-title><source>Am J Manag Care</source><year>2006</year><volume>12</volume><issue>5 Suppl</issue><fpage>S122</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">16613526</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12(5 Suppl):S122&#8211;128<pub-id pub-id-type="pmid">16613526</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verhamme</surname><given-names>KMC</given-names></name><name name-style="western"><surname>Dieleman</surname><given-names>JP</given-names></name><name name-style="western"><surname>van Wijk</surname><given-names>MAM</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>JLHR</given-names></name><name name-style="western"><surname>Stricker BHCh, Sturkenboom</surname><given-names>MCJM</given-names></name></person-group><article-title>Low incidence of acute urinary retention in the general male population: the triumph project</article-title><source>Eur Urol</source><year>2005</year><volume>47</volume><issue>4</issue><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2004.11.011</pub-id><pub-id pub-id-type="pmid">15774248</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Verhamme KMC, Dieleman JP, van Wijk MAM, Bosch JLHR, Stricker BHCh, Sturkenboom MCJM (2005) Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 47(4):494&#8211;498. 10.1016/j.eururo.2004.11.011<pub-id pub-id-type="pmid">15774248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2004.11.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></name><name name-style="western"><surname>Eryuzlu</surname><given-names>LN</given-names></name><name name-style="western"><surname>Cartwright</surname><given-names>R</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Tammela</surname><given-names>TLJ</given-names></name><name name-style="western"><surname>Guyatt</surname><given-names>GH</given-names></name><etal/></person-group><article-title>What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women</article-title><source>Eur Urol</source><year>2014</year><volume>65</volume><issue>6</issue><fpage>1211</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2014.01.019</pub-id><pub-id pub-id-type="pmid">24486308</pub-id><pub-id pub-id-type="pmcid">PMC4018666</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Agarwal A, Eryuzlu LN, Cartwright R, Thorlund K, Tammela TLJ, Guyatt GH et al (2014) What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 65(6):1211&#8211;1217. 10.1016/j.eururo.2014.01.019<pub-id pub-id-type="pmid">24486308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2014.01.019</pub-id><pub-id pub-id-type="pmcid">PMC4018666</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welliver</surname><given-names>C</given-names></name><name name-style="western"><surname>Feinstein</surname><given-names>L</given-names></name><name name-style="western"><surname>Ward</surname><given-names>JB</given-names></name><name name-style="western"><surname>Fwu</surname><given-names>CW</given-names></name><name name-style="western"><surname>Kirkali</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bavendam</surname><given-names>T</given-names></name><etal/></person-group><article-title>Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the urologic diseases in America project</article-title><source>J Urol</source><year>2020</year><volume>203</volume><issue>1</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1097/JU.0000000000000499</pub-id><pub-id pub-id-type="pmid">31430232</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Welliver C, Feinstein L, Ward JB, Fwu CW, Kirkali Z, Bavendam T et al (2020) Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the urologic diseases in America project. J Urol 203(1):171&#8211;178. 10.1097/JU.0000000000000499<pub-id pub-id-type="pmid">31430232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JU.0000000000000499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Cornu JN, Gacci M, Hashim H, Hermann TRW, Malde S, Netsch C et al (2025) EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid April 2025. ISBN 978-94-92671-29-5</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lerner</surname><given-names>LB</given-names></name><name name-style="western"><surname>McVary</surname><given-names>KT</given-names></name><name name-style="western"><surname>Barry</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bixler</surname><given-names>BR</given-names></name><name name-style="western"><surname>Dahm</surname><given-names>P</given-names></name><name name-style="western"><surname>Das</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-Surgical evaluation and treatment</article-title><source>J Urol</source><year>2021</year><volume>206</volume><issue>4</issue><fpage>818</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1097/JU.0000000000002184</pub-id><pub-id pub-id-type="pmid">34384236</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-Surgical evaluation and treatment. J Urol 206(4):818&#8211;826. 10.1097/JU.0000000000002184<pub-id pub-id-type="pmid">34384236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JU.0000000000002184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornu</surname><given-names>JN</given-names></name><name name-style="western"><surname>Zantek</surname><given-names>P</given-names></name><name name-style="western"><surname>Burtt</surname><given-names>G</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A</given-names></name><name name-style="western"><surname>Springate</surname><given-names>C</given-names></name><etal/></person-group><article-title>Minimally invasive treatments for benign prostatic obstruction: A systematic review and network Meta-analysis</article-title><source>Eur Urol</source><year>2023</year><volume>83</volume><issue>6</issue><fpage>534</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2023.02.028</pub-id><pub-id pub-id-type="pmid">36964042</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Cornu JN, Zantek P, Burtt G, Martin C, Martin A, Springate C et al (2023) Minimally invasive treatments for benign prostatic obstruction: A systematic review and network Meta-analysis. Eur Urol 83(6):534&#8211;547. 10.1016/j.eururo.2023.02.028<pub-id pub-id-type="pmid">36964042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2023.02.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roehrborn</surname><given-names>CG</given-names></name><name name-style="western"><surname>Barkin</surname><given-names>J</given-names></name><name name-style="western"><surname>Gange</surname><given-names>SN</given-names></name><name name-style="western"><surname>Shore</surname><given-names>ND</given-names></name><name name-style="western"><surname>Giddens</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. Study</article-title><source>Can J Urol</source><year>2017</year><volume>24</volume><issue>3</issue><fpage>8802</fpage><lpage>8813</lpage><pub-id pub-id-type="pmid">28646935</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. Study. Can J Urol 24(3):8802&#8211;8813<pub-id pub-id-type="pmid">28646935</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rukstalis</surname><given-names>D</given-names></name><name name-style="western"><surname>Grier</surname><given-names>D</given-names></name><name name-style="western"><surname>Stroup</surname><given-names>SP</given-names></name><name name-style="western"><surname>Tutrone</surname><given-names>R</given-names></name><name name-style="western"><surname>deSouza</surname><given-names>E</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prostatic urethral lift (Pul) for obstructive median lobes: 12 month results of the medlift study</article-title><source>Prostate Cancer Prostatic Dis</source><year>2019</year><volume>22</volume><issue>3</issue><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/s41391-018-0118-x</pub-id><pub-id pub-id-type="pmid">30542055</pub-id><pub-id pub-id-type="pmcid">PMC6760566</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S et al (2019) Prostatic urethral lift (Pul) for obstructive median lobes: 12 month results of the medlift study. Prostate Cancer Prostatic Dis 22(3):411&#8211;419. 10.1038/s41391-018-0118-x<pub-id pub-id-type="pmid">30542055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41391-018-0118-x</pub-id><pub-id pub-id-type="pmcid">PMC6760566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feiertag</surname><given-names>JH</given-names></name><name name-style="western"><surname>Clark</surname><given-names>JY</given-names></name></person-group><article-title>National trends in surgical management for benign prostatic hyperplasia from 2013 to 2019 in the united States</article-title><source>Urol Pract</source><year>2024</year><volume>11</volume><issue>2</issue><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1097/UPJ.0000000000000504</pub-id><pub-id pub-id-type="pmid">38305182</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Feiertag JH, Clark JY (2024) National trends in surgical management for benign prostatic hyperplasia from 2013 to 2019 in the united States. Urol Pract 11(2):303&#8211;311. 10.1097/UPJ.0000000000000504<pub-id pub-id-type="pmid">38305182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/UPJ.0000000000000504</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alzahrani</surname><given-names>AM</given-names></name><name name-style="western"><surname>Alsowayan</surname><given-names>OS</given-names></name></person-group><article-title>Evaluating the construct validity of urolift simulator through a virtual learning experience of urology residents</article-title><source>Urol Annals</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>15</fpage><pub-id pub-id-type="doi">10.4103/ua.ua_124_21</pub-id><pub-id pub-id-type="pmcid">PMC10062504</pub-id><pub-id pub-id-type="pmid">37006222</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Alzahrani AM, Alsowayan OS (2022) Evaluating the construct validity of urolift simulator through a virtual learning experience of urology residents. Urol Annals 15(1):15. 10.4103/ua.ua_124_21<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ua.ua_124_21</pub-id><pub-id pub-id-type="pmcid">PMC10062504</pub-id><pub-id pub-id-type="pmid">37006222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilling</surname><given-names>PJ</given-names></name></person-group><article-title>Does the urolift <sup>&#174;</sup> device change things?</article-title><source>BJU Int</source><year>2017</year><volume>119</volume><issue>S5</issue><fpage>6</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/bju.13773</pub-id><pub-id pub-id-type="pmid">28544297</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gilling PJ (2017) Does the urolift <sup>&#174;</sup> device change things? BJU Int 119(S5):6&#8211;6. 10.1111/bju.13773<pub-id pub-id-type="pmid">28544297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.13773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Julieb&#248;-Jones</surname><given-names>P</given-names></name><name name-style="western"><surname>Somani</surname><given-names>BK</given-names></name><name name-style="western"><surname>Tzelves</surname><given-names>L</given-names></name><name name-style="western"><surname>Haugland</surname><given-names>JN</given-names></name><name name-style="western"><surname>Moen</surname><given-names>CA</given-names></name><name name-style="western"><surname>Honor&#233;</surname><given-names>A</given-names></name><etal/></person-group><article-title>Complications and device failures associated with urolift: findings from the MAUDE database</article-title><source>Urologia</source><year>2023</year><volume>90</volume><issue>4</issue><fpage>636</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1177/03915603231180016</pub-id><pub-id pub-id-type="pmid">37292024</pub-id><pub-id pub-id-type="pmcid">PMC10623594</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Julieb&#248;-Jones P, Somani BK, Tzelves L, Haugland JN, Moen CA, Honor&#233; A et al (2023) Complications and device failures associated with urolift: findings from the MAUDE database. Urologia 90(4):636&#8211;641. 10.1177/03915603231180016<pub-id pub-id-type="pmid">37292024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/03915603231180016</pub-id><pub-id pub-id-type="pmcid">PMC10623594</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>HH</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>DM</given-names></name><name name-style="western"><surname>Laborde</surname><given-names>E</given-names></name><name name-style="western"><surname>Jack</surname><given-names>G</given-names></name><name name-style="western"><surname>Chin</surname><given-names>PT</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>P</given-names></name><etal/></person-group><article-title>Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia</article-title><source>J Sex Med</source><year>2012</year><volume>9</volume><issue>2</issue><fpage>568</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2011.02568.x</pub-id><pub-id pub-id-type="pmid">22172161</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P et al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9(2):568&#8211;575. 10.1111/j.1743-6109.2011.02568.x<pub-id pub-id-type="pmid">22172161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1743-6109.2011.02568.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perera</surname><given-names>M</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Doi</surname><given-names>SAR</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>D</given-names></name></person-group><article-title>Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis</article-title><source>Eur Urol</source><year>2015</year><volume>67</volume><issue>4</issue><fpage>704</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2014.10.031</pub-id><pub-id pub-id-type="pmid">25466940</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Perera M, Roberts MJ, Doi SAR, Bolton D (2015) Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67(4):704&#8211;713. 10.1016/j.eururo.2014.10.031<pub-id pub-id-type="pmid">25466940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2014.10.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>HH</given-names></name><name name-style="western"><surname>Chin</surname><given-names>PT</given-names></name><name name-style="western"><surname>McNicholas</surname><given-names>TA</given-names></name><name name-style="western"><surname>Gill</surname><given-names>HS</given-names></name><name name-style="western"><surname>Plante</surname><given-names>MK</given-names></name><name name-style="western"><surname>Bruskewitz</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)</article-title><source>BJU Int</source><year>2011</year><volume>108</volume><issue>1</issue><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2011.10342.x</pub-id><pub-id pub-id-type="pmid">21554526</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC et al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82&#8211;88. 10.1111/j.1464-410X.2011.10342.x<pub-id pub-id-type="pmid">21554526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1464-410X.2011.10342.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNicholas</surname><given-names>TA</given-names></name><name name-style="western"><surname>Woo</surname><given-names>HH</given-names></name><name name-style="western"><surname>Chin</surname><given-names>PT</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>D</given-names></name><name name-style="western"><surname>Arjona</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sievert</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Minimally invasive prostatic urethral lift: surgical technique and multinational experience</article-title><source>Eur Urol</source><year>2013</year><volume>64</volume><issue>2</issue><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.01.008</pub-id><pub-id pub-id-type="pmid">23357348</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">McNicholas TA, Woo HH, Chin PT, Bolton D, Arjona MF, Sievert KD et al (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292&#8211;299. 10.1016/j.eururo.2013.01.008<pub-id pub-id-type="pmid">23357348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2013.01.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#248;nksen</surname><given-names>J</given-names></name><name name-style="western"><surname>Barber</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Speakman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Berges</surname><given-names>R</given-names></name><name name-style="western"><surname>Wetterauer</surname><given-names>U</given-names></name><name name-style="western"><surname>Greene</surname><given-names>D</given-names></name><etal/></person-group><article-title>Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study</article-title><source>Eur Urol</source><year>2015</year><volume>68</volume><issue>4</issue><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2015.04.024</pub-id><pub-id pub-id-type="pmid">25937539</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">S&#248;nksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D et al (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643&#8211;652. 10.1016/j.eururo.2015.04.024<pub-id pub-id-type="pmid">25937539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2015.04.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>RP</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>T</given-names></name><name name-style="western"><surname>Elterman</surname><given-names>D</given-names></name><name name-style="western"><surname>Chughtai</surname><given-names>B</given-names></name><name name-style="western"><surname>Rukstalis</surname><given-names>D</given-names></name><etal/></person-group><article-title>Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study</article-title><source>Prostate Cancer Prostatic Dis</source><year>2024</year><volume>27</volume><issue>3</issue><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1038/s41391-023-00741-8</pub-id><pub-id pub-id-type="pmid">37884615</pub-id><pub-id pub-id-type="pmcid">PMC11319193</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Kaplan S, Kaufman RP, Mueller T, Elterman D, Chughtai B, Rukstalis D et al (2024) Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study. Prostate Cancer Prostatic Dis 27(3):485&#8211;491. 10.1038/s41391-023-00741-8<pub-id pub-id-type="pmid">37884615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41391-023-00741-8</pub-id><pub-id pub-id-type="pmcid">PMC11319193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaltsas</surname><given-names>A</given-names></name><name name-style="western"><surname>Giannakodimos</surname><given-names>I</given-names></name><name name-style="western"><surname>Symeonidis</surname><given-names>EN</given-names></name><name name-style="western"><surname>Deligiannis</surname><given-names>D</given-names></name><name name-style="western"><surname>Stavropoulos</surname><given-names>M</given-names></name><name name-style="western"><surname>Symeonidis</surname><given-names>A</given-names></name><etal/></person-group><article-title>To Rez&#363;m or not to rez&#363;m: A narrative review of water vapor thermal therapy for benign prostatic hyperplasia</article-title><source>J Clin Med</source><year>2025</year><volume>14</volume><issue>12</issue><fpage>4254</fpage><pub-id pub-id-type="doi">10.3390/jcm14124254</pub-id><pub-id pub-id-type="pmid">40565999</pub-id><pub-id pub-id-type="pmcid">PMC12194174</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kaltsas A, Giannakodimos I, Symeonidis EN, Deligiannis D, Stavropoulos M, Symeonidis A et al (2025) To Rez&#363;m or not to rez&#363;m: A narrative review of water vapor thermal therapy for benign prostatic hyperplasia. J Clin Med 14(12):4254. 10.3390/jcm14124254<pub-id pub-id-type="pmid">40565999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm14124254</pub-id><pub-id pub-id-type="pmcid">PMC12194174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Das A, Morgan KL, Yafi F (2022) Water vapor thermal therapy: minimally invasive treatment for benign prostatic hyperplasia. J Endourol 36(S2). 10.1089/end.2022.0424. S-6-S-11<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/end.2022.0424</pub-id><pub-id pub-id-type="pmid">36154455</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cornu</surname><given-names>J</given-names></name><name name-style="western"><surname>Fourmarier</surname><given-names>M</given-names></name><name name-style="western"><surname>Saussine</surname><given-names>C</given-names></name><name name-style="western"><surname>Descazeaud</surname><given-names>A</given-names></name><name name-style="western"><surname>Azzouzi</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP)</article-title><source>BJU Int</source><year>2016</year><volume>117</volume><issue>3</issue><fpage>495</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1111/bju.13124</pub-id><pub-id pub-id-type="pmid">25781490</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Robert G, Cornu J, Fourmarier M, Saussine C, Descazeaud A, Azzouzi AR et al (2016) Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int 117(3):495&#8211;499. 10.1111/bju.13124<pub-id pub-id-type="pmid">25781490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.13124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramesmayer</surname><given-names>C</given-names></name><name name-style="western"><surname>Deininger</surname><given-names>S</given-names></name><name name-style="western"><surname>Pyrgidis</surname><given-names>N</given-names></name><name name-style="western"><surname>Lusuardi</surname><given-names>L</given-names></name><name name-style="western"><surname>Kunit</surname><given-names>T</given-names></name><name name-style="western"><surname>Pallauf</surname><given-names>M</given-names></name><etal/></person-group><article-title>The early learning curve of the bipolar enucleation of the prostate: a multicenter cohort study</article-title><source>World J Urol</source><year>2024</year><volume>42</volume><issue>1</issue><fpage>478</fpage><pub-id pub-id-type="doi">10.1007/s00345-024-05183-y</pub-id><pub-id pub-id-type="pmid">39115714</pub-id><pub-id pub-id-type="pmcid">PMC11310227</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ramesmayer C, Deininger S, Pyrgidis N, Lusuardi L, Kunit T, Pallauf M et al (2024) The early learning curve of the bipolar enucleation of the prostate: a multicenter cohort study. World J Urol 42(1):478. 10.1007/s00345-024-05183-y<pub-id pub-id-type="pmid">39115714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-024-05183-y</pub-id><pub-id pub-id-type="pmcid">PMC11310227</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enikeev</surname><given-names>D</given-names></name><name name-style="western"><surname>Morozov</surname><given-names>A</given-names></name><name name-style="western"><surname>Taratkin</surname><given-names>M</given-names></name><name name-style="western"><surname>Misrai</surname><given-names>V</given-names></name><name name-style="western"><surname>Rijo</surname><given-names>E</given-names></name><name name-style="western"><surname>Podoinitsin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Systematic review of the endoscopic enucleation of the prostate learning curve</article-title><source>World J Urol</source><year>2021</year><volume>39</volume><issue>7</issue><fpage>2427</fpage><lpage>2438</lpage><pub-id pub-id-type="doi">10.1007/s00345-020-03451-1</pub-id><pub-id pub-id-type="pmid">32940737</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Enikeev D, Morozov A, Taratkin M, Misrai V, Rijo E, Podoinitsin A et al (2021) Systematic review of the endoscopic enucleation of the prostate learning curve. World J Urol 39(7):2427&#8211;2438. 10.1007/s00345-020-03451-1<pub-id pub-id-type="pmid">32940737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-020-03451-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Hajj</surname><given-names>A</given-names></name><name name-style="western"><surname>Misrai</surname><given-names>V</given-names></name><name name-style="western"><surname>Nasrallah</surname><given-names>AA</given-names></name><name name-style="western"><surname>Labban</surname><given-names>ML</given-names></name><name name-style="western"><surname>Najdi</surname><given-names>JA</given-names></name><name name-style="western"><surname>Rijo</surname><given-names>E</given-names></name></person-group><article-title>Learning curve in aquablation: an international multicenter study</article-title><source>World J Urol</source><year>2022</year><volume>40</volume><issue>3</issue><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1007/s00345-021-03898-w</pub-id><pub-id pub-id-type="pmid">34988648</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">El Hajj A, Misrai V, Nasrallah AA, Labban ML, Najdi JA, Rijo E (2022) Learning curve in aquablation: an international multicenter study. World J Urol 40(3):773&#8211;779. 10.1007/s00345-021-03898-w<pub-id pub-id-type="pmid">34988648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-021-03898-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>LP</given-names></name></person-group><article-title>State of the art: advanced techniques for prostatic urethral lift for the relief of prostate obstruction under local anesthesia</article-title><source>Can J Urol</source><year>2017</year><volume>24</volume><issue>3</issue><fpage>8859</fpage><lpage>8864</lpage><pub-id pub-id-type="pmid">28646943</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Walsh LP (2017) State of the art: advanced techniques for prostatic urethral lift for the relief of prostate obstruction under local anesthesia. Can J Urol 24(3):8859&#8211;8864<pub-id pub-id-type="pmid">28646943</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez-Fern&#225;ndez</surname><given-names>LF</given-names></name><name name-style="western"><surname>Bernaschina-Bobadilla</surname><given-names>CP</given-names></name></person-group><article-title>Pelvic hematoma after urolift: A case report and literature review</article-title><source>Cureus</source><year>2023</year><volume>15</volume><issue>4</issue><fpage>e38193</fpage><pub-id pub-id-type="doi">10.7759/cureus.38193</pub-id><pub-id pub-id-type="pmid">37252539</pub-id><pub-id pub-id-type="pmcid">PMC10223866</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Rodr&#237;guez-Fern&#225;ndez LF, Bernaschina-Bobadilla CP (2023) Pelvic hematoma after urolift: A case report and literature review. Cureus 15(4):e38193. 10.7759/cureus.38193<pub-id pub-id-type="pmid">37252539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.38193</pub-id><pub-id pub-id-type="pmcid">PMC10223866</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhary</surname><given-names>MK</given-names></name><name name-style="western"><surname>Kolanukuduru</surname><given-names>KP</given-names></name><name name-style="western"><surname>Eraky</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>A</given-names></name><name name-style="western"><surname>Tillu</surname><given-names>N</given-names></name><name name-style="western"><surname>Sur</surname><given-names>H</given-names></name><etal/></person-group><article-title>Comparative outcomes of En-Bloc holmium laser enucleation of the prostate and transvesical Robot-Assisted simple prostatectomy for the management of benign prostatic hyperplasia: A Propensity-Matched analysis</article-title><source>J Endourol</source><year>2025</year><volume>39</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1089/end.2024.0601</pub-id><pub-id pub-id-type="pmid">39589800</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Choudhary MK, Kolanukuduru KP, Eraky A, Mohammed A, Tillu N, Sur H et al (2025) Comparative outcomes of En-Bloc holmium laser enucleation of the prostate and transvesical Robot-Assisted simple prostatectomy for the management of benign prostatic hyperplasia: A Propensity-Matched analysis. J Endourol 39(1):57&#8211;63. 10.1089/end.2024.0601<pub-id pub-id-type="pmid">39589800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/end.2024.0601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>BB</given-names></name><name name-style="western"><surname>Tayon</surname><given-names>K</given-names></name><name name-style="western"><surname>Madiraju</surname><given-names>S</given-names></name><name name-style="western"><surname>Carrion</surname><given-names>RE</given-names></name><name name-style="western"><surname>Perito</surname><given-names>P</given-names></name></person-group><article-title>Prostatic urethral lift: does size matter??</article-title><source>J Endourol</source><year>2018</year><volume>32</volume><issue>7</issue><fpage>635</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1089/end.2017.0855</pub-id><pub-id pub-id-type="pmid">29631445</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P (2018) Prostatic urethral lift: does size matter?? J Endourol 32(7):635&#8211;638. 10.1089/end.2017.0855<pub-id pub-id-type="pmid">29631445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/end.2017.0855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehner</surname><given-names>K</given-names></name><name name-style="western"><surname>Popat</surname><given-names>S</given-names></name><name name-style="western"><surname>Utech</surname><given-names>K</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J</given-names></name></person-group><article-title>Outcomes of prostatic urethral lift in a medically complex population at a veterans affairs hospital</article-title><source>BJUI Compass</source><year>2021</year><volume>3</volume><issue>3</issue><fpage>214</fpage><pub-id pub-id-type="doi">10.1002/bco2.126</pub-id><pub-id pub-id-type="pmid">35492222</pub-id><pub-id pub-id-type="pmcid">PMC9045564</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lehner K, Popat S, Utech K, Taylor J, Brooks M, Jones J (2021) Outcomes of prostatic urethral lift in a medically complex population at a veterans affairs hospital. BJUI Compass 3(3):214. 10.1002/bco2.126<pub-id pub-id-type="pmid">35492222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bco2.126</pub-id><pub-id pub-id-type="pmcid">PMC9045564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>BS</given-names></name><name name-style="western"><surname>Ko</surname><given-names>YH</given-names></name><name name-style="western"><surname>Song</surname><given-names>PH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BH</given-names></name></person-group><article-title>Prostatic urethral length as a predictive factor for surgical treatment of benign prostatic hyperplasia: a prospective, multiinstitutional study</article-title><source>Prostate Int</source><year>2018</year><volume>7</volume><issue>1</issue><fpage>30</fpage><pub-id pub-id-type="doi">10.1016/j.prnil.2018.06.002</pub-id><pub-id pub-id-type="pmid">30937296</pub-id><pub-id pub-id-type="pmcid">PMC6424679</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kim BS, Ko YH, Song PH, Kim TH, Kim KH, Kim BH (2018) Prostatic urethral length as a predictive factor for surgical treatment of benign prostatic hyperplasia: a prospective, multiinstitutional study. Prostate Int 7(1):30. 10.1016/j.prnil.2018.06.002<pub-id pub-id-type="pmid">30937296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prnil.2018.06.002</pub-id><pub-id pub-id-type="pmcid">PMC6424679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Hah</surname><given-names>YS</given-names></name><name name-style="western"><surname>Chung</surname><given-names>DY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>KS</given-names></name></person-group><article-title>Correlation of prostatic urethral angle with the severity of urinary symptom and peak flow rate in men with small prostate volume</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>8</issue><fpage>e104395</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0104395</pub-id><pub-id pub-id-type="pmid">25127394</pub-id><pub-id pub-id-type="pmcid">PMC4134204</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kang DH, Lee JY, Hah YS, Chung DY, Lee DH, Cho KS (2014) Correlation of prostatic urethral angle with the severity of urinary symptom and peak flow rate in men with small prostate volume. PLoS ONE 9(8):e104395. 10.1371/journal.pone.0104395<pub-id pub-id-type="pmid">25127394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0104395</pub-id><pub-id pub-id-type="pmcid">PMC4134204</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rochester</surname><given-names>M</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>R</given-names></name><name name-style="western"><surname>Page</surname><given-names>T</given-names></name><name name-style="western"><surname>Barber</surname><given-names>N</given-names></name><name name-style="western"><surname>Kavia</surname><given-names>R</given-names></name><name name-style="western"><surname>Thiruchelvam</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prostatic urethral lift for subjects in urinary retention (PULSAR): 12-Month results of a prospective controlled trial compared with real&#8208;world outcomes</article-title><source>BJUI Compass</source><year>2024</year><volume>5</volume><issue>1</issue><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1002/bco2.280</pub-id><pub-id pub-id-type="pmid">38179018</pub-id><pub-id pub-id-type="pmcid">PMC10764167</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Rochester M, Doherty R, Page T, Barber N, Kavia R, Thiruchelvam N et al (2024) Prostatic urethral lift for subjects in urinary retention (PULSAR): 12-Month results of a prospective controlled trial compared with real&#8208;world outcomes. BJUI Compass 5(1):60&#8211;69. 10.1002/bco2.280<pub-id pub-id-type="pmid">38179018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bco2.280</pub-id><pub-id pub-id-type="pmcid">PMC10764167</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>